Upgrade to SI Premium - Free Trial

Morgan Stanley Upgrades ResMed (RMD) to Overweight; can grow despite GLP-1 worries

October 27, 2023 6:28 AM
(Updated - October 27, 2023 8:29 AM EDT)

Morgan Stanley analyst Sean Laaman upgraded ResMed (NYSE: RMD) from Equalweight ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Hot Upgrades Upgrades

Next Articles